Scott P Levick1, David R Soto-Pantoja2, Jianli Bi3, W Gregory Hundley4, Alexander Widiapradja1, Edward J Manteufel1, Tancia W Bradshaw5, Giselle C Meléndez6. 1. Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA; Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, USA. 2. Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA; Surgery-Hypertension and Vascular Research, Wake Forest School of Medicine, Winston-Salem, NC, USA. 3. Department of Internal Medicine, Section on Cardiology, Wake Forest School of Medicine, Winston-Salem, NC, USA. 4. Department of Internal Medicine, Section on Cardiology, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Radiological Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA. 5. Surgery-Hypertension and Vascular Research, Wake Forest School of Medicine, Winston-Salem, NC, USA. 6. Department of Internal Medicine, Section on Cardiology, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Pathology, Section on Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: gmelende@wakehealth.edu.
Abstract
BACKGROUND: Cancer patients receiving anthracycline-based chemotherapy (Anth-bC) may experience early cardiac fibrosis, which could be an important contributing mechanism to the development of impaired left ventricular (LV) function. Substance P, a neuropeptide that predominantly acts via the neurokinin 1 receptor (NK-1R), contributes to adverse myocardial remodelling and fibrosis in other cardiomyopathies. We sought to determine if NK-1R blockade is effective against doxorubicin (Dox - a frequently used Anth-bC)-induced cardiac fibrosis and cardiomyocyte apoptosis. In addition, we explored the direct effects of Dox on cardiac fibroblasts. METHODS: Male Sprague-Dawley rats were randomised to receive saline, six cycles of Dox (1.5mg Dox/kg/cycle) or Dox with an NK-1R antagonist (L732138, 5mg/kg/daily through Dox treatment). At 8 weeks after the initial dose of Dox, LV function and histopathological myocardial fibrosis and cell apoptosis were assessed. Collagen secretion was measured in vitro to test direct Dox activation of cardiac fibroblasts. RESULTS: Rats undergoing Dox treatment (9mg/kg cumulative dose) developed cardiac fibrosis and cardiomyocyte apoptosis. NK-1R blockade partially mitigated cardiac fibrosis while completely preventing cardiomyocyte apoptosis. This resulted in improved diastolic function. Furthermore, we found that Dox had direct effects on cardiac fibroblasts to cause increased collagen production and enhanced cell survival. CONCLUSIONS: This study demonstrates that cardiac fibrosis induced by Anth-bC can be reduced by NK-1R blockade. The residual fibrotic response is likely due to direct Dox effects on cardiac fibroblasts to produce collagen.
BACKGROUND:Cancerpatients receiving anthracycline-based chemotherapy (Anth-bC) may experience early cardiac fibrosis, which could be an important contributing mechanism to the development of impaired left ventricular (LV) function. Substance P, a neuropeptide that predominantly acts via the neurokinin 1 receptor (NK-1R), contributes to adverse myocardial remodelling and fibrosis in other cardiomyopathies. We sought to determine if NK-1R blockade is effective against doxorubicin (Dox - a frequently used Anth-bC)-induced cardiac fibrosis and cardiomyocyte apoptosis. In addition, we explored the direct effects of Dox on cardiac fibroblasts. METHODS: Male Sprague-Dawley rats were randomised to receive saline, six cycles of Dox (1.5mg Dox/kg/cycle) or Dox with an NK-1R antagonist (L732138, 5mg/kg/daily through Dox treatment). At 8 weeks after the initial dose of Dox, LV function and histopathological myocardial fibrosis and cell apoptosis were assessed. Collagen secretion was measured in vitro to test direct Dox activation of cardiac fibroblasts. RESULTS:Rats undergoing Dox treatment (9mg/kg cumulative dose) developed cardiac fibrosis and cardiomyocyte apoptosis. NK-1R blockade partially mitigated cardiac fibrosis while completely preventing cardiomyocyte apoptosis. This resulted in improved diastolic function. Furthermore, we found that Dox had direct effects on cardiac fibroblasts to cause increased collagen production and enhanced cell survival. CONCLUSIONS: This study demonstrates that cardiac fibrosis induced by Anth-bC can be reduced by NK-1R blockade. The residual fibrotic response is likely due to direct Dox effects on cardiac fibroblasts to produce collagen.
Authors: Jochen Springer; Anika Tschirner; Arash Haghikia; Stephan von Haehling; Hind Lal; Aleksandra Grzesiak; Elena Kaschina; Sandra Palus; Mareike Pötsch; Karoline von Websky; Berthold Hocher; Celine Latouche; Frederic Jaisser; Lars Morawietz; Andrew J S Coats; John Beadle; Josep M Argiles; Thomas Thum; Gabor Földes; Wolfram Doehner; Denise Hilfiker-Kleiner; Thomas Force; Stefan D Anker Journal: Eur Heart J Date: 2013-08-29 Impact factor: 29.983
Authors: Laura Cove-Smith; Neil Woodhouse; Adam Hargreaves; Jason Kirk; Susan Smith; Sally A Price; Melanie Galvin; Catherine J Betts; Simon Brocklehurst; Alison Backen; John Radford; Kim Linton; Ruth A Roberts; Matthias Schmitt; Caroline Dive; Jonathan D Tugwood; Paul D Hockings; Howard R Mellor Journal: Toxicol Sci Date: 2014-03-27 Impact factor: 4.849
Authors: Tomas G Neilan; Otavio R Coelho-Filho; Diego Pena-Herrera; Ravi V Shah; Michael Jerosch-Herold; Sanjeev A Francis; Javid Moslehi; Raymond Y Kwong Journal: Am J Cardiol Date: 2012-08-21 Impact factor: 2.778
Authors: Prema Robinson; Armandina Garza; Jeffrey Moore; T Kris Eckols; Skakun Parti; Vishwanathan Balaji; Jesus Vallejo; David J Tweardy Journal: Int J Clin Exp Med Date: 2009-03-31
Authors: L Lee Dupuis; Sabrina Boodhan; Mark Holdsworth; Paula D Robinson; Richard Hain; Carol Portwine; Erin O'Shaughnessy; Lillian Sung Journal: Pediatr Blood Cancer Date: 2013-03-19 Impact factor: 3.167
Authors: Prema Robinson; Moses Kasembeli; Uddalak Bharadwaj; Nikita Engineer; Kris T Eckols; David J Tweardy Journal: Biomed Res Int Date: 2016-02-11 Impact factor: 3.411
Authors: Ece Ergir; Jorge Oliver-De La Cruz; Soraia Fernandes; Marco Cassani; Francesco Niro; Daniel Pereira-Sousa; Jan Vrbský; Vladimír Vinarský; Ana Rubina Perestrelo; Doriana Debellis; Natália Vadovičová; Stjepan Uldrijan; Francesca Cavalieri; Stefania Pagliari; Heinz Redl; Peter Ertl; Giancarlo Forte Journal: Sci Rep Date: 2022-10-18 Impact factor: 4.996
Authors: Hao Zhang; Lei Tian; Mengcheng Shen; Chengyi Tu; Haodi Wu; Mingxia Gu; David T Paik; Joseph C Wu Journal: Circ Res Date: 2019-07-10 Impact factor: 17.367
Authors: Mary F Barbe; Amanda R White; Brendan A Hilliard; Danielle M Salvadeo; Mamta Amin; Michele Y Harris; Geneva E Cruz; Lucas Hobson; Steven N Popoff Journal: J Musculoskelet Neuronal Interact Date: 2019-12-01 Impact factor: 2.041
Authors: Jan M Leerink; Mabel van de Ruit; Elizabeth A M Feijen; Leontien C M Kremer; Annelies M C Mavinkurve-Groothuis; Yigal M Pinto; Esther E Creemers; Wouter E M Kok Journal: J Mol Med (Berl) Date: 2021-05-29 Impact factor: 4.599